Safety of Thrombolysis during Cardiopulmonary Resuscitation
- 1 January 2003
- journal article
- case report
- Published by Springer Nature in Drug Safety
- Vol. 26 (6) , 367-379
- https://doi.org/10.2165/00002018-200326060-00001
Abstract
The prognosis is generally poor for patients who experience a cardiac arrest. The most common causes of sudden cardiac arrest are massive pulmonary embolism (PE) and acute myocardial infarction (MI). While thrombolysis is a first-line treatment option in massive PE and acute MI, cardiopulmonary resuscitation (CPR) has been regarded as a relative contraindication for thrombolysis because of the anticipated bleeding risk caused by traumatic cardiocompressions. However, an increasing number of case reports and clinical studies on thrombolysis during and after CPR highlight an increased frequency of the return of spontaneous circulation and a better neurological outcome of surviving patients. These effects are mainly due to the thrombolysis of macroscopic blood clots and the amelioration of microcirculatory reperfusion. This article reviews case reports and clinical studies of thrombolysis during and shortly after CPR in order to estimate the risk of severe bleeding events caused by CPR in association with thrombolysis compared with CPR without thrombolysis. Although thrombolysis per se can cause severe and potentially fatal haemorrhage, there is no evidence that severe bleeding events occur more often when thrombolysis is combined with cardiocompressions. In addition, by far the majority of bleeding complications can be treated effectively. Thus, in many cases, the possible benefit of thrombolysis during CPR seems to outweigh the potential risks. However, there may be a publication bias in some case reports and studies towards reporting successful rather than unsuccessful CPRs. In addition, not enough controlled clinical trials have yet been conducted. Therefore, data from large randomised, multicentre studies are needed to definitely answer the question of the relationship between safety and efficacy of this promising treatment option. We conclude that the currently available data do not indicate that thrombolysis contributes to a significant increase in bleeding complications when administered during CPR.Keywords
This publication has 90 references indexed in Scilit:
- How Safe is the Readministration of Streptokinase?Drug Safety, 1995
- Safety and efficacy of thrombolysis for acute myocardial infarction in patients with prolonged out-of-hospital cardiopulmonary resuscitationThe American Journal of Cardiology, 1994
- Frequency of complications of cardiopulmonary resuscitation after thrombolysis during acute myocardial infarctionThe American Journal of Cardiology, 1992
- Clinical risks of thrombolytic therapyThe American Journal of Cardiology, 1992
- Comparative safety of thrombolytic agentsThe American Journal of Cardiology, 1991
- Thrombolytic therapy in patients requiring cardiopulmonary resuscitationThe American Journal of Cardiology, 1991
- Thrombolytic therapy of massive pulmonary embolism during prolonged cardiac arrest using recombinant tissue-type plasminogen activatorAnnals of Emergency Medicine, 1989
- A Prospective Trial of Intravenous Streptokinase in Acute Myocardial Infarction (I.S.A.M.)New England Journal of Medicine, 1986
- Western Washington Randomized Trial of Intracoronary Streptokinase in Acute Myocardial InfarctionNew England Journal of Medicine, 1983
- Survival after Cardiopulmonary Resuscitation in the HospitalNew England Journal of Medicine, 1983